None
Quote | Akero Therapeutics Inc. (NYSE:AKRO)
Last: | $ |
---|---|
Change Percent: | -7.69% |
Open: | $27.10 |
Close: | $24.97 |
High: | $27.10 |
Low: | $24.64 |
Volume: | 89,888 |
Last Trade Date Time: | 02/12/2020 04:42:16 pm |
News | Akero Therapeutics Inc. (NYSE:AKRO)
(NewsDirect) Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was...
2024-04-19 17:10:14 ET More on ContraVir Seeking Alpha’s Quant Rating on ContraVir Historical earnings data for ContraVir Financial information for ContraVir Read the full article on Seeking Alpha For further details see: Hepion ends Phase ...
Message Board Posts | Akero Therapeutics Inc. (NYSE:AKRO)
Subject | By | Source | When |
---|---|---|---|
Profit taking :__:) | subslover | investorshub | 01/04/2023 6:51:52 PM |
WOW | TheFinalCD | investorshub | 12/29/2022 10:46:20 PM |
$54 | subslover | investorshub | 12/29/2022 6:30:34 PM |
Hit $50.01 today! | subslover | investorshub | 12/28/2022 7:27:55 PM |
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY | subslover | investorshub | 12/23/2022 1:12:24 PM |
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NYSE Market:
(NewsDirect) Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was...
2024-04-09 14:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Company") (NASDAQ:AKRO). Investors who purchased Akero securities are encouraged to obtain additional informat...